gene	chromosome	start	end	applicableMutationType	source	date	sourceEvent	sourceUrls	nctId	title	acronym	genderCriterium	countriesAndCities	hospitalsPerCity	treatment	treatmentApproachesDrugClass	treatmentApproachesTherapy	applicableCancerType	applicableDoid	blacklistCancerTypes	description	level	evidenceLevelDetails	direction	evidenceUrls
BRAF	7	140453136	140453137	MISSENSE	CKB_TRIAL	1970-01-01	600X	NCT1	study1	study1			Netherlands(Rotterdam)	Rotterdam(EMC)	Vemurafenib			Breast cancer	X			A	GUIDELINE	RESPONSIVE	http
BRAF	7	140453136	140453137	MISSENSE	CKB_EVIDENCE	2021-02-03	600X								Vemurafenib			Skin Melanoma	X		efficacy evidence	A	GUIDELINE	RESPONSIVE	http
